ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences
On February 6, 2025, ACELYRIN announced an agreement to merge with Alumis Inc. (Nasdaq: ALMS) in an all-stock transaction. The transaction is expected to close in the second quarter of 2025, subject ...
Acelyrin confirms unsolicited indication of interest from Concentra Biosciences
Acelyrin (SLRN) “confirmed receipt of an unsolicited indication of interest from Concentra Biosciences, LLC, of which Tang Capital Partners, LP ...
Acelyrin jumps 11% on acquisition offer from Concentra Biosciences
Acelyrin (NASDAQ:SLRN) received an unsolicited acquisition offer from Concentra Biosciences, controlled by Tang Capital Partners. The proposal includes a cash payment of $3.00 per share, along with a ...